[Analysis of the efficacy and survival of ixazomib-containing regimens in patients with refractory and relapsed multiple myeloma]

Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):680-684. doi: 10.3760/cma.j.issn.0253-2727.2022.08.011.
[Article in Chinese]
No abstract available

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Boron Compounds / therapeutic use
  • Dexamethasone / therapeutic use
  • Glycine / therapeutic use
  • Humans
  • Lenalidomide / therapeutic use
  • Multiple Myeloma* / drug therapy
  • Neoplasm Recurrence, Local / drug therapy

Substances

  • ixazomib
  • Boron Compounds
  • Lenalidomide
  • Glycine
  • Dexamethasone

Grants and funding

基金项目:首都卫生发展科研专项基金-自主创新类(2022-2-4013)